于晓茹,郑铭,高圆,王向东,张罗

• 1:首都医科大学附属北京同仁医院耳鼻咽喉头颈外科
• 2:北京市耳鼻咽喉科研究所北京市教委过敏性疾病北京实验室慢性鼻病新药及诊断技术研发北京市重点实验室
• 3:首都医科大学附属北京同仁医院变态反应(鼻过敏)科
• 4:首都医科大学附属北京同仁医院风湿免疫科

摘要(Abstract)：

嗜酸性肉芽肿性多血管炎(eosinophilic granulomatosis with polyangiitis, EGPA)常以哮喘、慢性鼻窦炎伴或不伴鼻息肉作为特征性初始表现。由于EGPA临床罕见，目前公众乃至部分临床医师对该病认知不足，导致早期诊断识别面临严重挑战。本文系统综述EGPA的流行病学特征、免疫病理机制及诊疗进展，重点解析其鼻腔鼻窦病变特征，强调鼻科医生在预警信号识别和诊断路径实施中的关键作用，旨在建立基于鼻科视角的早期诊疗策略，以期实现疾病的早期识别，避免诊断延误，最终改善患者的预后和长期结局。

关键词(KeyWords)： 嗜酸性肉芽肿性多血管炎;鼻息肉;哮喘;嗜酸性粒细胞增多;生物制剂

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(No:82171110、82471137);; 北京市卫生系统高层次公共卫生技术人才建设项目(No:领军人才-01-08、领军人才-02-09);; 北京市科技新星交叉合作项目(No:20220484226、20230484476);; 国家重点研发计划(No:2022YFC2504100);; 教育部长江学者创新团队(No:IRT13082);; 首都卫生发展科研专项重点攻关项目(No:2022-1-1091)

作者(Author): 于晓茹,郑铭,高圆,王向东,张罗

DOI: 10.13201/j.issn.2096-7993.2026.10.013

参考文献(References)：

• [1] Cler SJ,Ogden MA,Farrell NF,et al.When inflammation is not just inflammation:a review of systemic diseases of the nose and sinuses part 2:Granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis[J].Am J Otolaryngol,2024,45(3):104207.
• [2] Akella SS,Schlachter DM,Black EH,et al.Ophthalmic eosinophilic granulomatosis with polyangiitis(churg-strauss syndrome):a systematic review of the literature[J].Ophthalmic Plast Reconstr Surg,2019,35(1):7-16.
• [3] Churg J,Strauss L.Allergic granulomatosis,allergic angiitis,and periarteritis nodosa[J].Am J Pathol,1951,27(2):277-301.
• [4] Jennette JC,Falk RJ,Bacon PA,et al.2012 revised international chapel hill consensus conference nomenclature of vasculitides[J].Arthritis Rheumatism,2013,65(1):1-11.
• [5] Watts RA,Hatemi G,Burns JC,et al.Global epidemiology of vasculitis[J].Nat Rev Rheumatol,2022,18(1):22-34.
• [6] Li JN,Cui Z,Long JY,et al.The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China[J].Arthritis Res Ther,2018,20(1):226.
• [7] Greco A,Rizzo MI,De Virgilio A,et al.Churg-strauss syndrome[J].Autoimmun Rev,2015,14(4):341-348.
• [8] Sinico RA,Di Toma L,Maggiore U,et al.Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome[J].Arthritis Rheumatism,2005,52(9):2926-2935.
• [9] Sada KE,Kojo Y,Fairburn-Beech J,et al.The prevalence,burden of disease,and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan:a retrospective,descriptive cohort claims database study[J].Mod Rheumatol,2022,32(2):380-386.
• [10] Sada KE,Suzuki T,Joksaite S,et al.Trends in prevalence,treatment use,and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan:Real-world database analysis[J].Mod Rheumatol,2024,34(5):988-998.
• [11] White J,Dubey S.Eosinophilic granulomatosis with polyangiitis:a review[J].Autoimmun Rev,2023,22(1):103219.
• [12] Piga MA,Fraticelli P,Antonicelli L,et al.ANCA-negative EGPA:only eosinophils without vasculitis?Insights from anti-T2 biologics[J].Front Immunol,2023,14:1325299.
• [13] Lyons PA,Peters JE,Alberici F,et al.Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status[J].Nat Commun,2019,10(1):5120.
• [14] Sokolowska BM,Szczeklik WK,Wludarczyk AA,et al.ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis(EGPA):outcome and long-term follow-up of 50 patients from a single Polish center[J].Clin Exp Rheumatol,2014,32(3 Suppl 82):S41-S47.
• [15] 嗜酸性肉芽肿性多血管炎诊治多学科专家共识编写组.嗜酸性肉芽肿性多血管炎诊治多学科专家共识(2025年版)[J].中华结核和呼吸杂志，2025,48(5):418-439.
• [16] Sciascia S,Ponticelli C,Roccatello D.Pathogenesis-based new perspectives of management of ANCA-associated vasculitis[J].Autoimmun Rev,2022,21(3):103030.
• [17] Nagase H,Ueki S,Fujieda S.The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases:Asthma,eosinophilic granulomatosis with polyangiitis,and eosinophilic chronic rhinosinusitis[J].Allergol Int,2020,69(2):178-186.
• [18] 高雅丽，王威清，朱真真，等.趋化因子在嗜酸性慢性鼻-鼻窦炎伴鼻息肉中的价值研究[J].临床耳鼻咽喉头颈外科杂志，2017,31(18):1458-1461.
• [19] Hua LJ,Xie M.Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis[J].Ther Adv Respir Dis,2025,19:17534666251318615.
• [20] Trivioli G,Terrier B,Vaglio A.Eosinophilic granulomatosis with polyangiitis:understanding the disease and its management[J].Rheumatology(Oxford),2020,59(Suppl 3):iii84-iii94.
• [21] Mouthon L,Dunogue B,Guillevin L.Diagnosis and classification of eosinophilic granulomatosis with polyangiitis(formerly named Churg-Strauss syndrome)[J].J Autoimmun,2014,48-49:99-103.
• [22] Cottin V,Bel E,Bottero P,et al.Respiratory manifestations of eosinophilic granulomatosis with polyangiitis(Churg-Strauss)[J].Eur Respir J,2016,48(5):1429-1441.
• [23] 陈婧，李菁，杨云娇，等.嗜酸性肉芽肿性多血管炎146例患者临床特征分析[J].中华内科杂志，2020,59(5):360-365.
• [24] Nakamaru Y,Takagi D,Suzuki M,et al.Otologic and rhinologic manifestations of eosinophilic granulomatosis with polyangiitis[J].Audiol Neurootol,2016,21(1):45-53.
• [25] Petersen H,Gotz P,Both M,et al.Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck[J].Rhin,2015,53(3):277-285.
• [26] Iwata M,Fukutomi Y,Hamada Y,et al.Computed tomography findings of paranasal sinuses in patients with eosinophilic granulomatosis with polyangiitis:Comparison with other eosinophilic sinus diseases and clinical relevance of their severity[J].Allergol Int,2023,72(3):428-436.
• [27] Berti A,Boukhlal S,Groh M,et al.Eosinophilic granulomatosis with polyangiitis:the multifaceted spectrum of clinical manifestations at different stages of the disease[J].Expert Rev Clin Immunol,2020,16(1):51-61.
• [28] Bacciu A,Buzio C,Giordano D,et al.Nasal polyposis in churg-strauss syndrome[J].Laryngoscope,2008,118(2):325-329.
• [29] Low CM,Keogh KA,Saba ES,et al.Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis:clinical presentation and antineutrophil cytoplasmic antibodies[J].Int Forum Allergy Rhinol,2020,10(2):217-222.
• [30] Solans-Laqué R,Rúa-Figueroa I,Blanco Aparicio M,et al.Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis(EGPA)[J].Eur J Intern Med,2024,128:45-52.
• [31] Kang N,Shin J,Cho YS,et al.Intractable middle ear effusion in EGPA patients might cause permanent hearing loss:a case-control study[J].Allergy Asthma Clin Immunol,2022,18(1):68.
• [32] Aggarwal R,Ringold S,Khanna D,et al.Distinctions between diagnostic and classification criteria?[J].Arthritis Care Res,2015,67(7):891-897.
• [33] 嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识编写组.嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识[J].中华结核和呼吸杂志，2018,41(7):514-521.
• [34] Grayson PC,Ponte C,Suppiah R,et al.2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis[J].Ann Rheum Dis,2022,81(3):309-314.
• [35] Emmi G,Bettiol A,Gelain E,et al.Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis[J].Nat Rev Rheumatol,2023,19(6):378-393.
• [36] Vaglio A,Buzio C,Zwerina J.Eosinophilic granulomatosis with polyangiitis(C hurg-S trauss):state of the art[J].Allergy,2013,68(3):261-273.
• [37] Laudien M,Holl-Ulrich K.Biopsy diagnostics of ANCA-associated vasculitides in the ENT tract[J].Z Rheumatol,2023,82(1):53-55.
• [38] 侯小萌，肖楚吟，李菁，等.肺部受累嗜酸性肉芽肿性多血管炎的临床特点[J].中华临床免疫和变态反应杂志，2017,11(3):253-258.
• [39] Fijolek J,Radzikowska E.Eosinophilic granulomatosis with polyangiitis-Advances in pathogenesis,diagnosis,and treatment[J].Front Med,2023,10:1145257.
• [40] Liu Y,Kong XF,Zhang X,et al.SERPINA3,FGA,AGP1,ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment[J].Rheumatology,2025,64(3):1316-1325.
• [41] Sebastian A,Kosa??ka-W??giel J.A variety of clinical presentations of eosinophilic granulomatosis with polyangiitis:a comprehensive review[J].Reumatologia,2024,62(6):456-465.
• [42] Suzuki M,Nakazono A,Morita S,et al.Comparison of clinical characteristics of the nasal manifestations of eosinophilic granulomatosis with polyangiitis(EGPA)and eosinophilic chronic rhinosinusitis(ECRS)[J].Allergol Int,2021,70(1):143-144.
• [43] Yates M,Watts R,Bajema I,et al.Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts[J].RMD Open,2017,3(1):e000449.
• [44] Samson M,Puéchal X,Devilliers H,et al.Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis(Churg-Strauss syndrome)enrolled in two prospective trials[J].J Autoimmun,2013,43:60-69.
• [45] Bettiol A,Urban ML,Bello F,et al.Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis(EGPA):a European multicentre observational study[J].Ann Rheum Dis,2022,81(12):1769-1772.
• [46] Teixeira V,Mohammad AJ,Jones RB,et al.Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis[J].RMD Open,2019,5(1):e000905.
• [47] Terrier B,Pugnet G,de Moreuil C,et al.Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis:a randomized controlled trial[J].Ann Intern Med,2025,178(9):1249-1257.
• [48] Wechsler ME,Akuthota P,Jayne D,et al.Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis[J].N Engl J Med,2017,376(20):1921-1932.
• [49] Kolbeck R,Kozhich A,Koike M,et al.MEDI-563,a humanized anti-IL-5 receptor alpha MAb with enhanced antibody-dependent cell-mediated cytotoxicity function[J].J Allergy Clin Immunol,2010,125(6):1344-1353.
• [50] Wechsler ME,Nair P,Terrier B,et al.Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis[J].N Engl J Med,2024,390(10):911-921.
• [51] Canzian A,Venhoff N,Urban ML,et al.Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis:data from a European collaborative study[J].Arthritis Rheumatol,2021,73(3):498-503.
• [52] Celebi Sozener Z,Gorgulu B,Mungan D,et al.Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis(EGPA):single-center experience in 18 cases[J].World Allergy Organ J,2018,11(1):39.
• [53] Olaguibel JM,Sastre J,Rodríguez JM,et al.Eosinophilia induced by blocking the IL-4/IL-13 pathway:potential mechanisms and clinical outcomes[J].J Investig Allergol Clin Immunol,2022,32(3):165-180.
• [54] Pendolino AL,Unadkat S,Zhang H,et al.The role of surgery in antineutrophil cytoplasmic antibody-associated vasculitides affecting the nose and sinuses:a systematic review[J].SAGE Open Med,2020,8:2050312120936731.
• [55] Kumar N,Jett SD,Gomes PL,et al.Eosinophilic granulomatosis with polyangiitis:a real-world study of biologics and sinus surgery use for managing nasal polyposis[J].Int Forum Allergy Rhinol,2025,15(6):608-615.
• [56] Guillevin L,Pagnoux C,Seror R,et al.The Five-Factor Score revisited:assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group(FVSG)cohort[J].Medicine,2011,90(1):19-27.
• [57] Comarmond C,Pagnoux C,Khellaf M,et al.Eosinophilic granulomatosis with polyangiitis(Churg-Strauss):clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort[J].Arthritis Rheum,2013,65(1):270-281.